Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA Turns To Outsider Oschmann To Head Pharma Unit

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck & Co.'s emerging markets head Stefan Oschmann will succeed Merck KGaA's Elmar Schnee as head of pharmaceuticals effective Jan. 1.

You may also be interested in...



Merck Serono/Dr. Reddy's Biosimilars Deal Includes Co-Commercialization In U.S.

In most of the world, Germany's Merck Serono will have exclusive rights and India’s Dr. Reddy's will receive royalties on the oncology biosimilars which will be developed as part of the collaboration; but in the U.S. and select emerging markets, the Indian company retains co-commercialization rights.

Merck Serono/Dr. Reddy's Biosimilars Deal Includes Co-Commercialization In U.S.

In most of the world, Germany's Merck Serono will have exclusive rights and India’s Dr. Reddy's will receive royalties on the oncology biosimilars which will be developed as part of the collaboration; but in the U.S. and select emerging markets, the Indian company retains co-commercialization rights.

Merck KGaA 2010 Results Marred By Cladribine And Poor OTC Growth

Millipore acquisition boosts 2010 results for Germany's Merck, but pharma strategy remains unclear.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel